Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: A multicenter retrospective analysis

Breast Cancer Research and Treatment

Volumn 147, Issue 1, 2014, Pages 103-112

  Niikura, Naoki ^a,b   Hayashi, Naoki ^c   Masuda, Norikazu ^d   Takashima, Seiki ^e   Nakamura, Rikiya ^f   Watanabe, Ken Ichi ^g   Kanbayashi, Chizuko ^h   Ishida, Mayumi ⁱ   Hozumi, Yasuo ^j   Tsuneizumi, Michiko ^k   Kondo, Naoto ^l   Naito, Yoichi ^m,n   Honda, Yayoi ^o   Matsui, Akira ^p   Fujisawa, Tomomi ^q   Oshitanai, Risa ^a   Yasojima, Hiroyuki ^d   Tokuda, Yutaka ^a   Saji, Shigehira ^b   Iwata, Hiroji ^l  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^d OSAKA NATIONAL HOSPITAL   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^f CHIBA CANCER CENTER   (Japan)

^g HOKKAIDO CANCER CENTER   (Japan)

^h NIIGATA CANCER CENTER HOSPITAL   (Japan)

ⁱ NATIONAL KYUSHU CANCER CENTER   (Japan)

^j JICHI MEDICAL UNIVERSITY   (Japan)

^k SHIZUOKA GENERAL HOSPITAL   (Japan)

^l AICHI CANCER CENTER HOSPITAL   (Japan)

^m NATIONAL CANCER CENTER   (Japan)

ⁿ NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^o TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^p NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^q GUNMA PREFECTURAL CANCER CENTER   (Japan)

more..

Author keywords

Brain metastases; Breast cancer; Retrospective analysis; Subtype

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; ASYMPTOMATIC DISEASE; BRAIN METASTASIS; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE COURSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL TIME; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CANCER GRADING; CLASSIFICATION; CLINICAL TRIAL; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; SECONDARY; SURVIVAL RATE;

BRAIN NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84906066755     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3090-8     Document Type: Article

References (31)

1. Klos KJ, O'Neill BP (2004) Brain metastases. Neurologist 10(1):31-46. doi:10.1097/01.nrl.0000106922.83090.7101.nrl.0000106922.83090.71
2. Frisk G, Svensson T, Backlund LM, Lidbrink E, Blomqvist P, Smedby KE (2012) Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden. Br J Cancer 106(11):1850-1853. doi:10.1038/bjc.2012. 163bjc2012163
3. Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13(6):1648-1655. doi:10.1158/1078-0432.CCR-06-2478
4. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, Yood MU, Yardley DA (2011) Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17(14):4834-4843. doi:10.1158/1078-0432.CCR-10-296217/14/4834
5. Crivellari D, Pagani O, Veronesi A, Lombardi D, Nole F, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Sessa C, Goldhirsch A (2001) High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12(3):353-356
6. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19(7):1242-1248. doi:10.1093/annonc/mdn036mdn036
7. Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Lang I, Wardley A, Lichinitser M, Sanchez RI, Muller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D (2013) CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol 14(3):244-248. doi:10.1016/S1470-2045(13)70017-2S1470-2045(13)70017-2
8. Tomasello G, Bedard PL, de Azambuja E, Lossignol D, Devriendt D, Piccart-Gebhart MJ (2010) Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib. Crit Rev Oncol Hematol 75(2):110-121. doi:10.1016/j.critrevonc.2009.11.003S1040-8428(09)00227-3
9. Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL (2013) Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol 24(6):1526-1533. doi:10.1093/annonc/mdt036
10. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97(12):2972-2977. doi:10.1002/cncr.11436
11. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44(5):1913-1918
12. Engel J, Eckel R, Aydemir U, Aydemir S, Kerr J, Schlesinger-Raab A, Dirschedl P, Holzel D (2003) Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 55(5):1186-1195
13. Hall WA, Djalilian HR, Nussbaum ES, Cho KH (2000) Long-term survival with metastatic cancer to the brain. Med Oncol 17(4):279-286
14. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363(9422):1665-1672. doi:10.1016/S0140-6736(04)16250-8S0140-6736(04)16250-8
15. Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17):3608-3617. doi:10.1200/JCO.2004.01.17522/17/3608
16. Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, Rudas M, Mader RM, Poetter R, Zielinski CC, Steger GG (2007) Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol 85(3):311-317. doi:10.1007/s11060-007-9420-5
17. Church DN, Modgil R, Guglani S, Bahl A, Hopkins K, Braybrooke JP, Blair P, Price CG (2008) Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol 31(3):250-254. doi:10.1097/COC.0b013e31815a43c4
18. Yap YS, Cornelio GH, Devi BC, Khorprasert C, Kim SB, Kim TY, Lee SC, Park YH, Sohn JH, Sutandyo N, Wong DW, Kobayashi M, Landis SH, Yeoh EM, Moon H, Ro J (2012) Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer 107(7):1075-1082. doi:10.1038/bjc.2012.346bjc2012346
19. Black PM, Johnson MD (2004) Surgical resection for patients with solid brain metastases: current status. JNeurooncol 69(1-3):119-124
20. Alexander E 3rd, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, Kooy HM, Loeffler JS (1995) Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 87(1):34-40
21. Melisko ME, Moore DH, Sneed PK, De Franco J, Rugo HS (2008) Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 88(3):359-365. doi:10.1007/s11060- 008-9578-5
22. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752. doi:10.1038/35021093
23. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Cardoso F (2013) Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol 31(25):3083-3090. doi:10.1200/JCO.2012.46.1574
24. Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5(1):5-23. doi:10.1016/j.molonc.2010.11.003
25. Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC (2013) Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat 141(3):507-514. doi:10.1007/s10549-013-2711-y
26. Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X, Sneed PK, Suh J, Weil RJ, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2013) The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neurooncol 112(3):467-472. doi:10.1007/s11060-013-1083-9
27. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2012) Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 82(5):2111-2117. doi:10.1016/j.ijrobp.2011.02.027
28. The World Health Organization (1983) Histological typing of breast tumors. Neoplasma 30(1):113-123
29. Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1,409 cases of which 359 have been followed for 15 years. Br J Cancer 11(3):359-377
30. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4):419-425. doi:10.1200/JCO.2011.38.0527
31. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, Sledge GW Jr (2003) Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14(7):1072-1077